| Trial Name: |
Heart Failure
|
| Intro: |
FUSION II is a research study for patients who have recently been hospitalized with heart failure. The research study is designed to determine whether a medicine called nesiritide (Natrecor®) |
| Condition: |
|
| Description: |
FUSION II is a research study for patients who have recently been hospitalized with heart failure. The research study is designed to determine whether a medicine called nesiritide (Natrecor®) helps heart failure patients feel better or reduce the need to be hospitalized in the future. This medicine is currently FDA approved, and is used to improve shortness of breath in certain patients hospitalized for heart failure. The medicine will be given to patients to use while at home. During the trial, participants will see a heart failure physician, have blood tests, answer questionnaires, and take the study medicine. Participants will also continue their usual oral medicines. The trial is 6 months long: 4 months of once or twice weekly treatment, and then 2 months of follow-up. |
| Criteria: |
Participants must have moderate to severe heart failure which limits their activities or gives them symptoms at rest, and participants must have been hospitalized at least twice within the past year. Participants must also have reduced pumping function of the heart and also have at least mildly reduced kidney function. |
| Contact: |
For information or to register for screening in this trial please call HealthMatch at (216) 844-5000, or complete and submit the form below. |
Participant Confidentiality:
All information regarding participation in Clinical Trials is treated with the
utmost confidentiality. University Hospitals Case Medical Center and the
Division of Clinical Research recognize and respect the confidentiality of this
information. Access to information related to clinical trials and their
participants is restricted to authorized clinical trials personnel only.
Back